Applied Genetic Technologies Corporation (AGTC) reported a $52,000 increase in reported revenues in the fiscal third quarter ending March 31st in comparison to its reported revenues at the same time last year. This year in the fiscal third quarter, AGTC reported $284,000 in reported revenue. However, net loss has increased in that same time frame. This is due to necessary expenses to make the company more viable; examples are increased research and development spending, laboratory expansion, the hiring of more employees, and the costs associated with becoming incorporated. AGTC is a local firm that develops genetic treatment of rare eye diseases that is currently trading on the NASDAQ.